Mehabe score: 4 G Factor: 5 Piotski Score: 8 The stock has a rating . The mehabe team score is reflective of its fundamental and technical merits. A rating above 8 is considered good buy. The stock has a G-Factor of 5 and Piotski score of 8.
Description
Sanofi India is engaged in Business of Manufacture and sale of pharmaceutical products. Site:SANOFI Main Symbol:SANOFI
Stock trades at 7457.0, above its 50dma 7408.33. However it is trading below its 200dma 7719.71. The stock remains weak though short term bullish momentum supports price action. It needs to close above 7719.71 for bullish price action to continue
The 52 week high is at 9300.00 and the 52week low is at 6945.00
Price Chart
P/E Chart
Sales and Margin
Strengths
– is almost debt free.
– has been maintaining a healthy dividend payout of 162.97%
Weakness
– Stock is trading at 7.72 times its book value
-The company has delivered a poor sales growth of 4.55% over past five years.
-Earnings include an other income of Rs.563.60 Cr.
Competition
– The industry trades at a mean P/E of 44.1x. Astrazeneca Phar trades at the industry’s max P/E of 106.64x. SANOFI trades at a P/E of 29.3x
– Industry’s mean G-Factor is 3.4 while the mean Piotski score is 8.0. SANOFI has a G-Factor of 5 and Piotski scoreof 8.
– Average 1 month return for industry is 0.1%. The max 1- month return was given by Glaxosmi. Pharma: a return of 7.67 %
Quarterly Results
Sales for period ended Dec 2021 is Rs 688.0 cr compared to Rs 720.0 cr for period ended Dec 2020, a fall of 4.4%
.
vis-vis 167.0 for period ended Dec 2020 .
Operating Margins contracted -473.5 bps for period ended Dec 2021 vis-vis Dec 2020.
Company reported operating profit of Rs 127.0 cr for period ended Dec 2021 and operating profit margin at 18.5 % for same period.
The EPS for quarter ended Dec 2021 is Rs 39.25 compared to Rs 230.04 for previous quarter ended Sep 2021 and Rs 53.41 for Dec 2020.
Profit & Loss Statement
Profit&Loss Comments
Company reported sales of Rs 2957.0 cr for period ended Dec 2021 vis-vis sales of Rs 2902.0 cr for the period ended Dec 2020, a growth of 1.9%. The 3 year sales cagr stood at 2.2%.
Operating margins expanded to 26.0% for period ended Dec 2021 vis-vis 25.0% for period ended Dec 2020, expansion of 100.0 bps.
Net Profit reported at Rs 944.0 cr for period ended Dec 2021 vis-vis sales of Rs 478.0 cr for the period ended Dec 2020, rising 49.4%.
Company recorded a healthy Net Profit CAGR of 35.3% over the last 3 years
Balance Sheet Statement
Cash Flow Statement
Cash Flow comments
CashFlow from operating activities was positive.
Sales Growth
Profit Growth Statement
Profit Growth Statement
Stock Price CAGR
Return of Equity
General Comments
– The company has improved its Return on Equity (RoE) metric. The RoE on Last Year basis was 27.0% compared to 23.0% over the last 3 Years. – The stock has given a return of -7% on a 1 Year basis vis-vis a return of 8% over the last 3 Years. – The compounded sales growth on a TTM bassis is 2% vis-vis a compounded sales growth of 2% over the last 3 Years. – The compounded profit growth on a TTM basis is 15% vis-vis a compounded profit growth of 15% over the last 3 Years.
Ratios
Shareholding Pattern
– FII shareholding has remained largely constant. The Dec 2021 fii holding stood at 9.22% vis-vis 10.34% for Sep 2021 – Public shareholding has remained largely constant. The Dec 2021 public holding stood at 11.33% vis-vis 11.59% for Sep 2021
Conclusion
– is almost debt free.
– has been maintaining a healthy dividend payout of 162.97% – Stock is trading at 7.72 times its book value
-The company has delivered a poor sales growth of 4.55% over past five years.
-Earnings include an other income of Rs.563.60 Cr.
